(via TheNewswire)

Vancouver, British Columbia -  TheNewswire - February 18, 2026  –  MindBio Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6); (OTCQB:MBQIF),  (the “ Company ” or “ MindBio ”), a biotechnology company that is commercialising prediction technologies for drug and alcohol intoxication detection using speech analytics and artificial intelligence, is pleased to announce it will conduct a non-brokered private placement (the “ Offering ”) to raise gross proceeds of up to $650,000 to accelerate the development of its enterprise intoxication detection solution, including the production of proprietary hardware and edge technologies for remote deployment in the mining industry.

The Company will offer up to 1,083,333 units (each, an “ Unit ”) at a price of $0.60 per Unit for gross proceeds of up to $650,000. Each Unit will consist of one common share of the Company (each, a “ Share ”) and one Share purchase warrant (each, a “ Warrant ”). Each Warrant will entitle the holder to acquire an additional Share at a price of $0.80 for a period of thirty-six months following closing of the Offering, subject to accelerated expiry in the event the closing price of the Shares on the Canadian Securities Exchange exceeds $1.00 for ten consecutive trading days.

The Company is pursuing opportunities for the use of its technology in drug and alcohol intoxication detection in the mining industry. The Company intends to use the net proceeds from the Offering to accelerate the development and deployment of a proprietary hardware and edge technology which will enable the remote and scalable use of MindBio’s intoxication detection solution at mining sites, for recruitment of specialised personnel and for general working capital purposes.  

In connection with completion of the Offering, the Company will pay finders’ fees to eligible third-parties who have introduced subscribers to the Offering.  All securities issued in connection with the Offering will be subject to restrictions on resale for a period of four-months-and-one-day in accordance with applicable securities laws.  

Completion of the Offering remains subject to final board and regulatory approvals.

Further, subject to final board approval, the Company plans to offer certain consultants and employees of the Company up to 450,000 stock options, under the Company’s Omnibus Incentive Plan, with each stock option exercisable at a price of $0.75 per option and valid for a period of 12 months.

For further information, please contact:

Justin Hanka, Chief Executive Officer

+61 433140886

justin@mindbiotherapeutics.com

www.mindbiotherapeutics.com

About MindBio Therapeutics Corp.

MindBio is a biotechnology company that is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. The Company is now collecting data that will allow its prediction tool to work on other types of intoxication for use in consumer and enterprise environments.

Cautionary Note Concerning Forward-Looking Statements:

The press release contains “forward-looking statements” within the meaning of applicable securities laws, including but not limited to, the Company’s ability to complete the Offering and option grants on the terms announced, and the development of its enterprise platform using voice and powered by AI for use in detecting drug and alcohol intoxication. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “budget,” “believe,” “project,” “estimate,” “expect,” “scheduled,” “forecast,” “strategy,” “future,” “likely,” “may,” “to be,” “could,” “would,” “should,” “will” and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

Additionally, there are known and unknown risk factors that could cause the Company’s actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: the risk that the Company may not be able to raise the gross proceeds of the Offering; the failure to obtain the final regulatory approval; and technical challenges in the development or deployment of its enterprise platform; general economic, market and business conditions in Canada and Australia; market volatility; and unforeseen delays in timelines for any of the transactions or events described in this press release.  All forward-looking information is qualified in its entirety by this cautionary statement.

The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright (c) 2026 TheNewswire - All rights reserved.